HC Wainwright Increases ASP Isotopes (NASDAQ:ASPI) Price Target to $5.50

ASP Isotopes (NASDAQ:ASPI) had its price target hoisted by investment analysts at HC Wainwright from $5.25 to $5.50 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 77.42% from the company’s previous close.

ASP Isotopes Price Performance

ASPI traded down $0.06 during midday trading on Wednesday, reaching $3.10. 557,004 shares of the company’s stock were exchanged, compared to its average volume of 588,420. ASP Isotopes has a one year low of $0.28 and a one year high of $4.97. The firm has a market capitalization of $151.65 million, a price-to-earnings ratio of -6.33 and a beta of 5.03. The business has a 50-day simple moving average of $3.66 and a two-hundred day simple moving average of $2.36. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 0.01.

Insider Transactions at ASP Isotopes

In other ASP Isotopes news, Director Robert John Andrew Ryan purchased 15,596 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was purchased at an average cost of $2.35 per share, with a total value of $36,650.60. Following the acquisition, the director now directly owns 537,055 shares of the company’s stock, valued at approximately $1,262,079.25. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 26.30% of the stock is owned by insiders.

Hedge Funds Weigh In On ASP Isotopes

A number of large investors have recently modified their holdings of ASPI. Millennium Management LLC acquired a new stake in shares of ASP Isotopes during the fourth quarter worth $49,000. Armistice Capital LLC acquired a new position in ASP Isotopes in the first quarter valued at about $2,702,000. Renaissance Technologies LLC bought a new stake in shares of ASP Isotopes in the second quarter worth about $272,000. HTLF Bank bought a new stake in shares of ASP Isotopes in the fourth quarter worth about $141,000. Finally, Rathbones Group PLC acquired a new stake in shares of ASP Isotopes during the fourth quarter worth about $272,000. 16.80% of the stock is currently owned by institutional investors and hedge funds.

ASP Isotopes Company Profile

ASP Isotopes Inc, a pre-commercial stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It develops Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company also Uranium-235, an isotope of uranium for carbon-free energy industry.